argenx SE – American Depositary Shares (NASDAQ:ARGX) rose 12.8% during trading on Thursday . The company traded as high as $69.27 and last traded at $59.47. Approximately 2,869,004 shares traded hands during trading, an increase of 3,430% from the average daily volume of 81,283 shares. The stock had previously closed at $52.73.

ARGX has been the topic of a number of analyst reports. Zacks Investment Research cut argenx SE – American Depositary Shares from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Wedbush reiterated an “outperform” rating and set a $41.00 target price (up previously from $26.00) on shares of argenx SE – American Depositary Shares in a report on Thursday, November 16th. They noted that the move was a valuation call. Finally, Cowen reiterated a “buy” rating on shares of argenx SE – American Depositary Shares in a report on Thursday, August 24th.

Large investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. boosted its holdings in shares of argenx SE – American Depositary Shares by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 121,313 shares of the company’s stock worth $2,743,000 after purchasing an additional 2,167 shares during the last quarter. Nicholas Investment Partners LP acquired a new stake in shares of argenx SE – American Depositary Shares during the second quarter worth $236,000. DAFNA Capital Management LLC acquired a new stake in shares of argenx SE – American Depositary Shares during the second quarter worth $848,000. Artal Group S.A. acquired a new stake in shares of argenx SE – American Depositary Shares during the third quarter worth $1,229,000. Finally, Tekla Capital Management LLC acquired a new stake in shares of argenx SE – American Depositary Shares during the second quarter worth $1,591,000. Hedge funds and other institutional investors own 25.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “argenx SE – American Depositary Shares (ARGX) Stock Price Up 12.8%” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/argenx-se-american-depositary-shares-argx-stock-price-up-12-8/1764426.html.

About argenx SE – American Depositary Shares

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Receive News & Ratings for argenx SE - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx SE - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.